- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT02639793
Effects of Catheter Ablation on Burden of Atrial Fibrillation (MRICEMAN) (MRICEMAN)
A Nationwide Multicenter Trial Assessing the Effects of Catheter Ablation on Burden of Atrial Fibrillation Recorded by Implantable Cardiac Monitor
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
A total of 300 patients will be randomized to three different catheter ablation techniques (100 patients/group); radiofrequency ablation using remote magnet navigation, radiofrequency ablation using manual method, and cryoablation. A loop recorder (REVEAL) is implanted one month before the catheter ablation of paroxysmal atrial fibrillation and the effects of atrial fibrillation burden will be compared between the three methods at 12 and 24 months after ablation excluding the first three months´ blanking period.
The primary endpoints are:
- the proportion of patients remaining free from atrial fibrillation, atrial flutter or atrial tachycardia (> 2 minutes) recorded by the implantable cardiac monitor (Medtronic) at 24 months follow-up and
- total atrial fibrillation burden recorded by the loop recorder.
Other endpoints:
- Atrial fibrillation burden in 7 days Holter recording at 12 and 24 months compared to baseline,
- the time to first documented symptomatic and asymptomatic recurrence of atrial fibrillation
- prescription of antiarrhythmic drugs after the 3 months blanking period following the ablation
- re-ablation after the index ablation procedure,
- total procedural duration;
- total time of fluoroscopy and radiation dose;
- number and duration of cardiovascular hospitalization;
- quality of life questionnaires at 12 months and 24 month compared with baseline,
- cognitive function at 12 and 24 month compared with baseline,
- cost-efficacy of the different ablation techniques.
Tipo de estudio
Inscripción (Anticipado)
Fase
- Fase 4
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Oulu, Finlandia, 90014
- UOulu
-
Oulu, Finlandia
- Heikki Huikuri
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion criteria:
- Patients with symptomatic paroxysmal atrial fibrillation fulfilling the contemporary guideline criteria for AF ablation
Exclusion Criteria:
- Any contraindication to catheter ablation
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Único
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Comparador activo: manual radiofrequency ablation
Radiofrequency catheter ablation using manual catheter manipulation will be used as an ablation technique.
|
Three different catheter ablation techniques will be used aimed at isolating the pulmonary veins from left atrium.The endpoint is defined as absence or dissociation of all pulmonary vein potentials as confirmed by the circular mapping catheter after a waiting period of 30 minutes after the last ablation.
The use of adenosine or isoproterenol to detect concealed pulmonary vein conduction is voluntary.
|
|
Comparador activo: magnet navigation ablation
Radiofrequency catheter ablation using remote magnet navigation will be used as an ablation technique.
|
Three different catheter ablation techniques will be used aimed at isolating the pulmonary veins from left atrium.The endpoint is defined as absence or dissociation of all pulmonary vein potentials as confirmed by the circular mapping catheter after a waiting period of 30 minutes after the last ablation.
The use of adenosine or isoproterenol to detect concealed pulmonary vein conduction is voluntary.
|
|
Comparador activo: cryoablation
Catheter ablation using cryoablation technique will be used as an ablation technique of atrial fibrillation.
|
Three different catheter ablation techniques will be used aimed at isolating the pulmonary veins from left atrium.The endpoint is defined as absence or dissociation of all pulmonary vein potentials as confirmed by the circular mapping catheter after a waiting period of 30 minutes after the last ablation.
The use of adenosine or isoproterenol to detect concealed pulmonary vein conduction is voluntary.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Free of atrial fibrillation
Periodo de tiempo: 24 months
|
the proportion of patients remaining free from AF, atrial flutter (AFL) or atrial tachycardia (AT) (> 2 minutes) recorded by the implantable cardiac monitor (ICM, Reveal, Medtronic Co.) at 24 months.
|
24 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Total AF burden
Periodo de tiempo: 24 months
|
total AF burden recorded by the implantable loop recorder during the 24 month follow-up.
|
24 months
|
|
Incidence of adverse events
Periodo de tiempo: 24 months
|
Safety is one of the secondary endpoints. The following potential adverse events will be monitored: Any previous left atrial ablation or surgery Any cardiac surgery or percutaneous coronary intervention within three months prior to enrolment. Secondary AF Stroke or transient ischemic attack within six months prior to enrolment Myocardial infarction within three months prior to enrolment Left ventricular ejection fraction < 40 % Anteroposterior left atrial diameter >55 mm by transthoracic or transesophageal echocardiography Implanted prosthetic valve |
24 months
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Heikki Huikuri, Prof, University of Oulu
Publicaciones y enlaces útiles
Enlaces Útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Anticipado)
Finalización del estudio (Anticipado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Estimar)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- AFOulu
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .